The phenylthiourea is a competitive inhibitor of the enzymatic oxidation of DOPA by phenoloxidase.

21:57 EDT 21st August 2014 | BioPortfolio

Summary of "The phenylthiourea is a competitive inhibitor of the enzymatic oxidation of DOPA by phenoloxidase."

Phenoloxidase is a key enzyme of melanization catalyzing the oxidation of phenols. Phenylthiourea (PTU) is the well-known and widely used inhibitor of phenoloxidase. However, the mechanism of its action is not quite clear. In the present work, the effect of PTU on the enzymatic oxidation of 3-(3,4-dihydroxyphenyl)-l-alanine (DOPA) by phenoloxidase was studied by spectrophotometric methods. The inhibition constant of PTU was estimated as 0.21 ± 0.09 µM and the competitive type of inhibition was determined for this reaction.

Affiliation

Institute of Chemical Kinetics and Combustion, Laboratory of Chemistry and Physics of Free Radicals, Institutskaya 3, Novosibirsk, Russian Federation.

Journal Details

This article was published in the following journal.

Name: Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Pages:

Links

PubMed Articles [6448 Associated PubMed Articles listed on BioPortfolio]

Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinson's disease.

The molecular mechanisms for the loss of 3,4-dihydroxyphenylalanine (L-dopa) efficacy during the treatment of Parkinson's disease (PD) are unknown. Modifications related to catecholamine metabolism su...

L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.

L-dopa remains the mainstay treatment for Parkinson's disease (PD), although in later stages, treatment is complicated by L-dopa-induced dyskinesias (LID). Current evidence links LID to excessive stri...

Preparation of Tween 80-Zn/Al-Levodopa-Layered Double Hydroxides Nanocomposite for Drug Delivery System.

We incorporated anti-Parkinsonian drug, levodopa (dopa), in Zn/Al-LDH by coprecipitation method to form dopa-LDH nanocomposite. Further coating of Tween-80 on the external surfaces of dopa-LDH nanocom...

Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.

The aim of the study was to determine whether the dopamine (DA) precursor L-DOPA attenuates parkinsonian-like symptoms produced by the ubiquitin-proteasome system inhibitor lactacystin. Wistar rats we...

Defining a kinetic mechanism for L-DOPA 2,3 dioxygenase, a single-domain type I extradiol dioxygenase from Streptomyces lincolnensis.

L-DOPA-2,3-dioxygenase from Streptomyces lincolnensis is a single domain type I extradiol dioxygenase of the vicinal oxygen chelate superfamily and catalyzes the second step in the metabolism of the p...

Clinical Trials [1152 Associated Clinical Trials listed on BioPortfolio]

Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer

Medullary thyroid carcinoma (MTC) is a rare tumor arising from C cells of the thyroid gland and belonging to the endocrine tumors. 18F-DOPA PET, based on tha capacity of endocrine tumor ce...

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

This Phase IIb exploratory study is designed to determine whether AFQ056 is safe and effective and whether it can increase the therapeutic window of L-dopa in patients whose control of the...

Study of Protein Translocation in Patients With Beta-Oxidation Disorders

OBJECTIVES: I. Characterize inheritance patterns of mutations in patients with beta-oxidation disorders.

Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

Children with congenital hyperinsulinism have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with the University of Pennsylvania wil...

A New Enzymatic Assay for Rapid Diagnosing of Central Nervous System Enteroviral Infection

A new enzymatic assay was developed by NMD Diagnostics for rapid diagnosis of Enteroviral CNS infection. This study will compare this assay to RT-PCR, by testing human CSF samples taken fr...

Medical and Biotech [MESH] Definitions

One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of dopa to dopamine. It is of clinical importance in the treatment of Parkinson's disease. EC 4.1.1.28.

Isoprostanes derived from the free radical oxidation of ARACHIDONIC ACID. Although similar in structure to enzymatically synthesized prostaglandin F2alpha (DINOPROST), they occur through non-enzymatic oxidation of cell membrane lipids.

An enzyme of the oxidoreductase class that catalyzes the reaction between L-tyrosine, L-dopa, and oxygen to yield L-dopa, dopaquinone, and water. It is a copper protein that acts also on catechols, catalyzing some of the same reactions as CATECHOL OXIDASE. EC 1.14.18.1.

A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed)

An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.

Search BioPortfolio: